主动监测期间前列腺癌患者预防疾病进展的非手术干预:系统综述与Meta分析
该系统综述与Meta分析检索PubMed、Scopus和Web of Science,纳入22项研究(6项随机对照试验、16项观察性研究),评估主动监测期间延缓前列腺癌进展的干预措施。5α还原酶抑制剂与无进展生存期改善相关(HR 0.59,95%CI 0.48-0.72),且未增加毒性信号;维生素D3、氯地孕酮、非沙波肽三氟乙酸酯和恩扎卢胺显示一定疗效,但抗癌药物相关不良事件发生率高达88%。
要点
- 5α还原酶抑制剂与主动监测患者无进展生存期改善相关(HR 0.59,95%CI 0.48-0.72),未增加毒性信号。
- 维生素D3、氯地孕酮、非沙波肽三氟乙酸酯和恩扎卢胺显示一定疗效,但抗癌药物相关不良事件发生率高达88%。
- 其他干预措施证据薄弱,难以得出明确结论,需更多研究确定疗效和安全性。
核心结论
- 5α还原酶抑制剂用于主动监测的前列腺癌患者与更长的无进展生存期相关(HR 0.59,95%CI 0.48-0.72)。
- 对于其他干预措施,基于现有薄弱证据难以得出明确结论。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Scopus和Web of Science数据库。
- 纳入22项研究,包括6项随机对照试验和16项观察性研究。
- 主要终点为前列腺癌进展,其定义必须包括病理升级;次要终点包括治疗毒性。
主要发现
- 5α还原酶抑制剂给药与无进展生存期改善相关(HR 0.59,95%CI 0.48-0.72),无毒性信号增加。
- 维生素D3、氯地孕酮、非沙波肽三氟乙酸酯和恩扎卢胺等治疗显示一定疗效,但治疗相关不良事件发生率高达88%。
- 评估的干预措施包括5α还原酶抑制剂、他汀类药物、饮食、运动、氯地孕酮、非沙波肽三氟乙酸酯、恩扎卢胺、咖啡、维生素D3和PROSTVAC。
关键数值与推荐
- 5α还原酶抑制剂与无进展生存期改善相关:HR 0.59(95%CI 0.48-0.72)。
- 抗癌药物(维生素D3、氯地孕酮、非沙波肽三氟乙酸酯、恩扎卢胺)治疗相关不良事件发生率高达88%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 除5α还原酶抑制剂外,其他干预措施基于现有薄弱证据难以得出明确结论。
- 其他干预措施需要更多研究来确定其在主动监测男性中的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Active surveillance (AS) is a standard of care for patients with low-risk and selected intermediate-risk prostate cancer (PCa). Nevertheless, there is a lack of summary evidence on how to impact disease trajectory during AS. OBJECTIVE: To assess which interventions prevent PCa progression effectively during AS. EVIDENCE ACQUISITION: We queried PubMed, Scopus, and Web of Science databases to identify studies examining the impact of interventions aimed at slowing disease progression during AS. The primary endpoint was PCa progression, the definition of which must have included pathological upgrading. The secondary endpoint included treatment toxicities. EVIDENCE SYNTHESIS: We identified 22 studies, six randomized controlled trials and 16 observational studies, which analyzed the association between different interventions and PCa progression during AS. The interventions considered in the studies included 5-alpha reductase inhibitors (5-ARIs), statins, diet, exercise, chlormadinone, fexapotide triflutate (FT), enzalutamide, coffee, vitamin D3, and PROSTVAC. We found that administration of 5-ARIs was associated with improved progression-free survival (PFS; hazard ratio: 0.59; 95% confidence interval 0.48-0.72), with no increased toxicity signals. Therapies such as vitamin D3, chlormadinone, FT, and enzalutamide have shown some efficacy. However, these anticancer drugs have been associated with treatment-related adverse events in up to 88% of patients. CONCLUSIONS: The use of 5-ARIs in PCa patients on AS is associated with longer PFS. However, for the other interventions, it is difficult to draw clear conclusions based on the weak available evidence. PATIENT SUMMARY: Patients with prostate cancer managed with active surveillance (AS) who are treated with 5-alpha reductase inhibitors have a lower risk of disease progression, with minimal adverse events. Other interventions require more studies to determine their efficacy and safety profile in men on AS.
引用
- Matsukawa A, Yanagisawa T, Bekku K, et al. Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2023. PMID: 38277189. doi:10.1016/j.euo.2023.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。